October 8, 2021
“The paradox of aggregated abeta:
how it can be a great biomarker
but a poor target for therapy.”
presented by:
David S. Knopman, MD
Professor of Neurology, Investigator in Mayo Alzheimer’s Disease Research Center, Mayo Clinic, Rochester MN
David S. Knopman, M.D. is a clinical neurologist involved in research in late-life cognitive disorders, such as mild cognitive impairment and dementia. Dr. Knopman's specific interests are in the very early stages of Alzheimer's disease, in cognitive impairment due to stroke (cerebrovascular disease) and in cognitive impairment due to frontotemporal degeneration. He is involved in epidemiology, clinical trials and diagnostic studies of these disorders.
Dr. Knopman's primary role is as a clinician, and he sees patients with various cognitive disorders nearly every day. Therefore, goals of his research are, first, to improve diagnostic accuracy and, second, to find better treatments for patients with Alzheimer's disease, frontotemporal degeneration and cerebrovascular cognitive disorders.
Hosted by Dr. Mony J. de Leon